Subscribe: WSJ.com: Markets
http://online.wsj.com/xml/rss/3_7031.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
barclays  drug  equity  life aberdeen  life  markets  money  peak  prescription  private equity  private  prove  purveyor  standard life 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: WSJ.com: Markets

WSJ.com: Markets



Markets



Last Build Date: Sun, 25 Feb 2018 08:43:05 EST

Copyright: copyright © 2018 Dow Jones & Company, Inc.
 



Hidden Profits In the Prescription Drug Supply Chain

Sat, 24 Feb 2018 21:56:20 EST

Depending on how you look at them, pharmacy-benefit managers are either low-margin middlemen that fight to reduce drug costs, or highly profitable intermediaries that take a cut of every prescription and earn more when drug prices rise.



Anbang and the Financialization of China's Economy

Fri, 23 Feb 2018 05:19:07 EST

Beijing just took over China’s most notorious purveyor of dodgy wealth management products. The next phase of the debt crackdown might prove more damaging.



Why General Mills Is Paying Up for a Dog's Breakfast

Fri, 23 Feb 2018 14:41:10 EST

The cereal and ice cream maker needs to shift to protein and is buying Blue Buffalo Pet Products, a purveyor of high-protein, natural pet foods, to do it.



New HPs Give Fresh Life to Old Businesses

Fri, 23 Feb 2018 08:35:41 EST

The two companies created from the old Hewlett-Packard have surprised investors—but they still need to prove the growth is sustainable.



Where Peak Optimism Has Reached Its Peak

Fri, 23 Feb 2018 08:13:27 EST

There could be change afoot in European markets, as the reassurance of data in consistently beating expectations fades.



Who Wins From Standard Life Aberdeen-Phoenix Deal

Fri, 23 Feb 2018 13:17:11 EST

Standard Life Aberdeen thinks shedding its insurance arm will unlock value. But what is left behind is an asset manager with high costs and investor outflows. Both need fixing, fast.



How Gargantuan Can Private Equity Get?

Fri, 23 Feb 2018 00:44:08 EST

The biggest private-equity firms are in a fund-raising frenzy, but it will be increasingly hard to find the returns that have made them such money magnets.



A Reality Check for Wayfair

Thu, 22 Feb 2018 15:11:54 EST

Investors have been feverishly pushing up Wayfair’s stock despite the company’s growing losses, worsening free cash flow and surging marketing spending. That run may finally be coming to an end.



Why Barclays' Promises Are Still for Another Day

Thu, 22 Feb 2018 15:43:41 EST

If Barclays has the money now for bigger shareholder payouts, why isn’t it making them? The answer shows the risks for investors.